Proteus Digital Health, a maker of ingestible sensors inside drugs formerly known as Vivomems, has raised $62.5m in its series F round from a corporation including database provider Oracle as a new investor.
Oracle joined repeat investors Otsuka Pharmaceutical Company, Novartis and Sino Portfolio, which is thought to be connected to China-based Dong Ying Pharma (also called Sino Biological).
Oracle said alongside its “strategic minority investment in Proteus” it expected exclusivity to provide clinical investigators worldwide the ability to measure information about medication ingestion, dose timing, and associated physiologic response continuously and precisely for patients enrolled in clinical trials using the portfolio company’s digital medicines.
Oracle added it would integrate Proteus’ ingestible sensor with its clinical trial products, such as Oracle Health Sciences InForm, Oracle Life Sciences Data Hub and Oracle’s Siebel Clinical Trial Management System.
Neil de Crescenzo, senior vice-president of Oracle Health Sciences Global Business Unit, said: “We are looking forward to integrating Proteus’ technology into Oracle’s cloud-based clinical trial platform.”
In early 2010, Novartis said it had invested $24m into Proteus to use its technology for organ transplants. A regulatory filing at the end of 2009 showed a further $25m was raised.
In October 2008, Proteus raised $32m in its D round from corporate venturing groups at Medtronic and Itochu as new investors. They joined a consortium including St Jude Medical, Adams Street Partners, Carlyle Group, Essex Woodlands, Kaiser Permanente Ventures and Spring Ridge Ventures.
And further regulatory filing showed $33m was garnered at the end of 2006 and $3.5m in mid-2004.
Proteus said it partnered with and licensed to Otsuka, Novartis, Medtronic and Kaiser Permanente, as well as Avery Dennison, ON Semiconductor and Lloydspharmacy.
Andrew Thompson, chief executive of Proteus, said: “By embedding Proteus technology into established, market leading products & services we are changing healthcare and empowering patients, physicians and researchers with digital technology.”